Combination of letrozole, metronomic cyclophosphamide and sorafenib is well-tolerated and shows activity in patients with primary breast cancer

British Journal of Cancer

Volumn 112, Issue 1, 2015, Pages 52-60

  Bazzola, L ^a,i   Foroni, C ^a,i   Andreis, D ^a,i   Zanoni, V ^a,i   Cappelletti, M R ^a,i   Allevi, G ^a,i   Aguggini, S ^a,i   Strina, C ^a,i   Milani, M ^a,i   Venturini, S ^a,i   Ferrozzi, F ^b,i   Giardini, R ^c,i   Bertoni, R ^c,i   Turley, H ^d,i   Gatter, K ^d,i   Petronini, P G ^e,i   Fox, S B ^f,i   Harris, A L ^g,i   Martinotti, M ^h,i   Berruti, A ^h,i   Bottini, A ^a,i   Reynolds, A R ^i,j   Generali, D ^a,i   more..

^a UO di Patologia Mammaria Breast Cancer Unit US Terapia Molecolare e Farmacogenomica AO Istituti Ospitalieri di Cremona   (Italy)

^b Istituti Ospitalieri di Cremona   (Italy)

^c UO di Anatomia Patologica   (Italy)

^d UNIVERSITY OF OXFORD   (United Kingdom)

^e UNIVERSITY OF PARMA   (Italy)

^f PETER MACCALLUM CANCER CENTRE   (Australia)

^g UNIVERSITY OF OXFORD   (United Kingdom)

^h UO Chirurgia Generale   (Italy)

ⁱ Department of Medical Oncology Azienda Spedali Civili ^*  (Italy)

^j INSTITUTE OF CANCER RESEARCH   (United Kingdom)

more..

Author keywords

breast cancer; endocrine resistance; letrozole; neoadjuvant; primary hormone therapy; sorafenib

Indexed keywords

CD31 ANTIGEN; CYCLOPHOSPHAMIDE; FLUORODEOXYGLUCOSE F 18; KI 67 ANTIGEN; LETROZOLE; SORAFENIB; VASCULOTROPIN A; ANTINEOPLASTIC AGENT; CARBANILAMIDE DERIVATIVE; NICOTINAMIDE; NITRILE; TRIAZOLE DERIVATIVE; TUMOR MARKER;

ACNE; ALOPECIA; ANOREXIA; AREA UNDER THE CURVE; ARTHRALGIA; ARTICLE; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CLINICAL ARTICLE; COMPUTER ASSISTED EMISSION TOMOGRAPHY; DEHYDRATION; DIARRHEA; DRUG BLOOD LEVEL; DRUG ERUPTION; DRUG HALF LIFE; DRUG INDUCED HEADACHE; FATIGUE; FEMALE; HAND FOOT SYNDROME; HUMAN; HYPERTENSION; IMMUNOHISTOCHEMISTRY; MAXIMUM PLASMA CONCENTRATION; MUCOSA INFLAMMATION; NEUTROPENIA; NUCLEAR MAGNETIC RESONANCE IMAGING; PLASMA CONCENTRATION-TIME CURVE; POSTMENOPAUSE; RIGOR; SEGMENTAL MASTECTOMY; SENSORY NEUROPATHY; TUMOR VOLUME; WEIGHT REDUCTION; AGED; ANALOGS AND DERIVATIVES; BREAST NEOPLASMS; METABOLISM; METRONOMIC DRUG ADMINISTRATION; MIDDLE AGED; RANDOMIZED CONTROLLED TRIAL (TOPIC);

ADMINISTRATION, METRONOMIC; AGED; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CYCLOPHOSPHAMIDE; FEMALE; HUMANS; MIDDLE AGED; NIACINAMIDE; NITRILES; PHENYLUREA COMPOUNDS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TRIAZOLES; TUMOR MARKERS, BIOLOGICAL;

EID: 84920642492     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/bjc.2014.563     Document Type: Article

References (42)

1. Albain KS, Barlow WE, Ravdin PM, Farrar WB, Burton GV, Ketchel SJ, Cobau CD, Levine EG, Ingle JN, Pritchard KI, Lichter AS, Schneider DJ, Abeloff MD, Henderson IC, Muss HB, Green SJ, Lew D, Livingston RB, Martino S, Osborne CK. Breast Cancer Intergroup of North A (2009) Adjuvant chemotherapy and timing of tamoxifen in postmenopausal patients with endocrine-responsive, node-positive breast cancer: a phase 3, open-label, randomised controlled trial. Lancet 374(9707): 2055-2063.
2. Baselga J, Segalla JG, Roche H, Del Giglio A, Pinczowski H, Ciruelos EM, Filho SC, Gomez P, Van Eyll B, Bermejo B, Llombart A, Garicochea B, Duran MA, Hoff PM, Espie M, de Moraes AA, Ribeiro RA, Mathias C, Gil Gil M, Ojeda B, Morales J, Kwon Ro S, Li S, Costa F (2012) Sorafenib in combination with capecitabine: an oral regimen for patients with HER2-negative locally advanced or metastatic breast cancer. J Clin Oncol 30(13): 1484-1491.
3. Bodini M, Berruti A, Bottini A, Allevi G, Fiorentino C, Brizzi MP, Bersiga A, Generali D, Volpi D, Marini U, Aguggini S, Tampellini M, Alquati P, Olivetti L, Dogliotti L (2004) Magnetic resonance imaging in comparison to clinical palpation in assessing the response of breast cancer to epirubicin primary chemotherapy. Breast Cancer Res Treatment 85(3): 211-218.
4. Bonelli MA, Fumarola C, Alfieri RR, La Monica S, Cavazzoni A, Galetti M, Gatti R, Belletti S, Harris AL, Fox SB, Evans DB, Dowsett M, Martin LA, Bottini A, Generali D, Petronini PG (2010) Synergistic activity of letrozole and sorafenib on breast cancer cells. Breast Cancer Res Treatment 124(1): 79-88.
5. Bottini A, Generali D, Brizzi MP, Fox SB, Bersiga A, Bonardi S, Allevi G, Aguggini S, Bodini G, Milani M, Dionisio R, Bernardi C, Montruccoli A, Bruzzi P, Harris AL, Dogliotti L, Berruti A (2006) Randomized phase II trial of letrozole and letrozole plus low-dose metronomic oral cyclophosphamide as primary systemic treatment in elderly breast cancer patients. J Clin Oncol 24(22): 3623-3628.
6. Calleri A, Bono A, Bagnardi V, Quarna J, Mancuso P, Rabascio C, Dellapasqua S, Campagnoli E, Shaked Y, Goldhirsch A, Colleoni M, Bertolini F (2009) Predictive potential of angiogenic growth factors and circulating endothelial cells in breast cancer patients receiving metronomic chemotherapy plus bevacizumab. Clin Cancer Res 15(24): 7652-7657.
7. Chang TK, Yu L, Maurel P, Waxman DJ (1997) Enhanced cyclophosphamide and ifosfamide activation in primary human hepatocyte cultures: response to cytochrome P-450 inducers and autoinduction by oxazaphosphorines. Cancer Res 57(10): 1946-1954.
8. Choi H, Charnsangavej C, Faria SC, Macapinlac HA, Burgess MA, Patel SR, Chen LL, Podoloff DA, Benjamin RS (2007) Correlation of computed tomography and positron emission tomography in patients with metastatic gastrointestinal stromal tumor treated at a single institution with imatinib mesylate: proposal of new computed tomography response criteria. J Clin Oncol 25(13): 1753-1759.
9. Dowsett M, Smith IE, Ebbs SR, Dixon JM, Skene A, Griffith C, Boeddinghaus I, Salter J, Detre S, Hills M, Ashley S, Francis S, Walsh G, Trialists I (2005) Short-term changes in Ki-67 during neoadjuvant treatment of primary breast cancer with anastrozole or tamoxifen alone or combined correlate with recurrence-free survival. Clin Cancer Res 11(2 Pt 2): 951s-958ss.
10. Generali D, Buffa FM, Berruti A, Brizzi MP, Campo L, Bonardi S, Bersiga A, Allevi G, Milani M, Aguggini S, Papotti M, Dogliotti L, Bottini A, Harris AL, Fox SB (2009) Phosphorylated ERalpha, HIF-1alpha, and MAPK signaling as predictors of primary endocrine treatment response and resistance in patients with breast cancer. J Clin Oncol 27(2): 227-234.
11. Generali D, Fox SB, Brizzi MP, Allevi G, Bonardi S, Aguggini S, Milani M, Bersiga A, Campo L, Dionisio R, Vergoni F, Giardini R, Dogliotti L, Bottini A, Harris AL, Berruti A (2008) Down-regulation of phosphatidylinositol 3'-kinase/AKT/molecular target of rapamycin metabolic pathway by primary letrozole-based therapy in human breast cancer. Clin Cancer Res 14(9): 2673-2680.
12. Gervot L, Rochat B, Gautier JC, Bohnenstengel F, Kroemer H, de Berardinis V, Martin H, Beaune P, de Waziers I (1999) Human CYP2B6: expression, inducibility and catalytic activities. Pharmacogenetics 9(3): 295-306.
13. Gligorov J, Azria D, Namer M, Khayat D, Spano JP (2007) Novel therapeutic strategies combining antihormonal and biological targeted therapies in breast cancer: focus on clinical trials and perspectives. Crit Rev Oncol Hematol 64(2): 115-128.
14. Gomez P, Lacouture ME (2011) Clinical presentation and management of hand-foot skin reaction associated with sorafenib in combination with cytotoxic chemotherapy: experience in breast cancer. Oncologist 16(11): 1508-1519.
15. Gradishar WJ, Kaklamani V, Sahoo TP, Lokanatha D, Raina V, Bondarde S, Jain M, Ro SK, Lokker NA, Schwartzberg L (2013) A double-blind, randomised, placebo-controlled, phase 2b study evaluating sorafenib in combination with paclitaxel as a first-line therapy in patients with HER2-negative advanced breast cancer. Eur J Cancer 49(2): 312-322.
16. Guller U, Nitzsche EU, Schirp U, Viehl CT, Torhorst J, Moch H, Langer I, Marti WR, Oertli D, Harder F, Zuber M (2002) Selective axillary surgery in breast cancer patients based on positron emission tomography with 18F-fluoro-2-deoxy-D-glucose: not yet! Breast Cancer Res Treatment 71(2): 171-173.
17. Huynh H, Ngo VC, Koong HN, Poon D, Choo SP, Thng CH, Chow P, Ong HS, Chung A, Soo KC (2009) Sorafenib and rapamycin induce growth suppression in mouse models of hepatocellular carcinoma. J Cell Mol Med 13(8B): 2673-2683.
18. Isaacs C, Herbolsheimer P, Liu MC, Wilkinson M, Ottaviano Y, Chung GG, Warren R, Eng-Wong J, Cohen P, Smith KL, Creswell K, Novielli A, Slack R (2011) Phase I/II study of sorafenib with anastrozole in patients with hormone receptor positive aromatase inhibitor resistant metastatic breast cancer. Breast Cancer Res Treatment 125(1): 137-143.
19. Iyer R, Fetterly G, Lugade A, Thanavala Y (2010) Sorafenib: a clinical and pharmacologic review. Expert Opin Pharmacother 11(11): 1943-1955.
20. Johnston SR, Martin LA, Head J, Smith I, Dowsett M (2005) Aromatase inhibitors: combinations with fulvestrant or signal transduction inhibitors as a strategy to overcome endocrine resistance. J Steroid Biochem Mol Biol 95(1-5): 173-181.
21. Johnston SR, Martin LA, Leary A, Head J, Dowsett M (2007) Clinical strategies for rationale combinations of aromatase inhibitors with novel therapies for breast cancer. J Steroid Biochem Mol Biol 106(1-5): 180-186.
22. Kelemen PR, Lowe V, Phillips N (2002) Positron emission tomography and sentinel lymph node dissection in breast cancer. Clin Breast Cancer 3(1): 73-77.
23. Keswani RN, Chumsangsri A, Mustafi R, Delgado J, Cohen EE, Bissonnette M (2008) Sorafenib inhibits MAPK-mediated proliferation in a Barrett's esophageal adenocarcinoma cell line. Dis Esophagus 21(6): 514-521.
24. Koukourakis MI, Giatromanolaki A, Sivridis E, Gatter KC, Harris AL. Tumour, Angiogenesis Research G (2005) Inclusion of vasculature-related variables in the Dukes staging system of colon cancer. Clin Cancer Res 11(24 Pt 1): 8653-8660.
25. Kumar SM, Yu H, Edwards R, Chen L, Kazianis S, Brafford P, Acs G, Herlyn M, Xu X (2007) Mutant V600E BRAF increases hypoxia inducible factor-1alpha expression in melanoma. Cancer Res 67(7): 3177-3184.
26. Le Goff P, Montano MM, Schodin DJ, Katzenellenbogen BS (1994) Phosphorylation of the human estrogen receptor. Identification of hormone-regulated sites and examination of their influence on transcriptional activity. J Biol Chem 269(6): 4458-4466.
27. Lindley C, Hamilton G, McCune JS, Faucette S, Shord SS, Hawke RL, Wang H, Gilbert D, Jolley S, Yan B, LeCluyse EL (2002) The effect of cyclophosphamide with and without dexamethasone on cytochrome P450 3A4 and 2B6 in human hepatocytes. Drug Metab Dispos 30(7): 814-822.
28. Mancuso P, Colleoni M, Calleri A, Orlando L, Maisonneuve P, Pruneri G, Agliano A, Goldhirsch A, Shaked Y, Kerbel RS, Bertolini F (2006) Circulating endothelial-cell kinetics and viability predict survival in breast cancer patients receiving metronomic chemotherapy. Blood 108(2): 452-459.
29. Massarweh S, Osborne CK, Creighton CJ, Qin L, Tsimelzon A, Huang S, Weiss H, Rimawi M, Schiff R (2008) Tamoxifen resistance in breast tumors is driven by growth factor receptor signaling with repression of classic estrogen receptor genomic function. Cancer Res 68(3): 826-833.
30. Mehta S, Hughes NP, Buffa FM, Li SP, Adams RF, Adwani A, Taylor NJ, Levitt NC, Padhani AR, Makris A, Harris AL (2011) Assessing early therapeutic response to bevacizumab in primary breast cancer using magnetic resonance imaging and gene expression profiles. J Natl Cancer Inst Monogr 2011(43): 71-74.
31. Montagna E, Cancello G, Dellapasqua S, Munzone E, Colleoni M (2014) Metronomic therapy and breast cancer: A systematic review. Cancer Treatment Rev 40(8): 942-950.
32. Nicholson RI, Hutcheson IR, Hiscox SE, Knowlden JM, Giles M, Barrow D, Gee JM (2005) Growth factor signalling and resistance to selective oestrogen receptor modulators and pure anti-oestrogens: the use of anti-growth factor therapies to treat or delay endocrine resistance in breast cancer. Endocr Relat Cancer 12(Suppl 1): S29-S36.
33. Nicholson RI, Hutcheson IR, Knowlden JM, Jones HE, Harper ME, Jordan N, Hiscox SE, Barrow D, Gee JM (2004) Nonendocrine pathways and endocrine resistance: observations with antiestrogens and signal transduction inhibitors in combination. Clin Cancer Res 10(1 Pt 2): 346S-354SS.
34. Osborne CK, Kitten L, Arteaga CL (1989) Antagonism of chemotherapyinduced cytotoxicity for human breast cancer cells by antiestrogens. J Clin Oncol 7(6): 710-717.
35. Osborne CK, Shou J, Massarweh S, Schiff R (2005) Crosstalk between estrogen receptor and growth factor receptor pathways as a cause for endocrine therapy resistance in breast cancer. Clin Cancer Res 11(2 Pt 2): 865s-870ss.
36. Pasquier E, Kavallaris M, Andre N (2010) Metronomic chemotherapy: new rationale for new directions. Nat Rev Clin Oncol 7(8): 455-465.
37. Schwartzberg LS, Tauer KW, Hermann RC, Makari-Judson G, Isaacs C, Beck JT, Kaklamani V, Stepanski EJ, Rugo HS, Wang W, Bell-McGuinn K, Kirshner JJ, Eisenberg P, Emanuelson R, Keaton M, Levine E, Medgyesy DC, Qamar R, Starr A, Ro SK, Lokker NA, Hudis CA (2013) Sorafenib or placebo with either gemcitabine or capecitabine in patients with HER-2-negative advanced breast cancer that progressed during or after bevacizumab. Clin Cancer Res 19(10): 2745-2754.
38. Smith IE, Dowsett M (2003) Aromatase inhibitors in breast cancer. N Engl J Med 348(24): 2431-2442.
39. Strumberg D, Clark JW, Awada A, Moore MJ, Richly H, Hendlisz A, Hirte HW, Eder JP, Lenz HJ, Schwartz B (2007) Safety, pharmacokinetics, and preliminary antitumor activity of sorafenib: a review of four phase I trials in patients with advanced refractory solid tumors. Oncologist 12(4): 426-437.
40. Strumberg D, Richly H, Hilger RA, Schleucher N, Korfee S, Tewes M, Faghih M, Brendel E, Voliotis D, Haase CG, Schwartz B, Awada A, Voigtmann R, Scheulen ME, Seeber S (2005) Phase I clinical and pharmacokinetic study of the Novel Raf kinase and vascular endothelial growth factor receptor inhibitor BAY 43-9006 in patients with advanced refractory solid tumors. J Clin Oncol 23(5): 965-972.
41. van der Hoeven JJ, Hoekstra OS, Comans EF, Pijpers R, Boom RP, van Geldere D, Meijer S, Lammertsma AA, Teule GJ (2002) Determinants of diagnostic performance of [F-18]fluorodeoxyglucose positron emission tomography for axillary staging in breast cancer. Ann Surg 236(5): 619-624.
42. Yang SX, Steinberg SM, Nguyen D, Wu TD, Modrusan Z, Swain SM (2008) Gene expression profile and angiogenic marker correlates with response to neoadjuvant bevacizumab followed by bevacizumab plus chemotherapy in breast cancer. Clin Cancer Res 14(18): 5893-5899.